How one father built a biotech, Grace Science, to save his daughter
Highlights Matt Wilsey has spent a decade and $70 million trying to develop a cure for his daughter…
FDA approves Vera Therapeutics kidney disease treatment
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Anthropic, AI powerhouse, announces it will begin developing drugs of its own
Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be…
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Summit Therapeutics (NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against…
Anthropic releases Claude Science, sees Claude Code level impact
Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be…
Definium LSD therapy for major depression helped patients in Phase 3 trial
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
FDA pilot program aims to speed up early-stage clinical trials
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Prometheus, Lilly, Nvidia, Abridge, Luvelta: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Lilly shares safety, tolerability data on its next-gen obesity drug
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
As drug discovery moves from trial-and-error to digital simulation, choosing between Recursion Pharmaceuticals (NASDAQ:RXRX) and Schrödinger (NASDAQ:SDGR) depends…
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Study conduct The trial was conducted from 19 May 2022 to 2 March 2026 (data cutoff date) in…
Revolution Medicines starts early access for pancreatic cancer drug
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…